MA33363B1 - Antagonistes de la voie de signalisation hedgehog a base de phtalazine disubstituee - Google Patents

Antagonistes de la voie de signalisation hedgehog a base de phtalazine disubstituee

Info

Publication number
MA33363B1
MA33363B1 MA34455A MA34455A MA33363B1 MA 33363 B1 MA33363 B1 MA 33363B1 MA 34455 A MA34455 A MA 34455A MA 34455 A MA34455 A MA 34455A MA 33363 B1 MA33363 B1 MA 33363B1
Authority
MA
Morocco
Prior art keywords
disubstituted
antagonists
phtalazine
signaling pathway
hedgehog signaling
Prior art date
Application number
MA34455A
Other languages
English (en)
Inventor
Philip Arthur Hipskind
Bharvin Kumar Patel
Nee Takakuwa Takako Wilson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA33363B1 publication Critical patent/MA33363B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention porte sur de nouveaux antagonistes de la voie hedgehog, phtalazine 1,4 disubstituée de formule (I), utiles dans le traitement du cancer.
MA34455A 2009-06-19 2010-06-15 Antagonistes de la voie de signalisation hedgehog a base de phtalazine disubstituee MA33363B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21862809P 2009-06-19 2009-06-19
PCT/US2010/038568 WO2010147917A1 (fr) 2009-06-19 2010-06-15 Antagonistes phtalazine disubstituée de la voie hedgehog

Publications (1)

Publication Number Publication Date
MA33363B1 true MA33363B1 (fr) 2012-06-01

Family

ID=42332981

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34455A MA33363B1 (fr) 2009-06-19 2010-06-15 Antagonistes de la voie de signalisation hedgehog a base de phtalazine disubstituee

Country Status (35)

Country Link
US (2) US8273742B2 (fr)
EP (1) EP2443104B1 (fr)
JP (1) JP5596139B2 (fr)
KR (1) KR101389165B1 (fr)
CN (1) CN102459233B (fr)
AR (1) AR077014A1 (fr)
AU (1) AU2010260244B2 (fr)
BR (1) BRPI1011601A2 (fr)
CA (1) CA2764542C (fr)
CL (1) CL2011003147A1 (fr)
CO (1) CO6480932A2 (fr)
CR (1) CR20110658A (fr)
DK (1) DK2443104T3 (fr)
DO (1) DOP2011000386A (fr)
EA (1) EA019059B1 (fr)
EC (1) ECSP11011541A (fr)
ES (1) ES2409054T3 (fr)
HN (1) HN2011003139A (fr)
HR (1) HRP20130408T1 (fr)
IL (1) IL216599A (fr)
JO (1) JO2931B1 (fr)
MA (1) MA33363B1 (fr)
MX (1) MX2011014029A (fr)
MY (1) MY156667A (fr)
NZ (1) NZ596882A (fr)
PE (1) PE20121050A1 (fr)
PL (1) PL2443104T3 (fr)
PT (1) PT2443104E (fr)
SG (1) SG177289A1 (fr)
SI (1) SI2443104T1 (fr)
TN (1) TN2011000627A1 (fr)
TW (1) TWI385165B (fr)
UA (1) UA106755C2 (fr)
WO (1) WO2010147917A1 (fr)
ZA (1) ZA201108587B (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7981892B2 (en) * 2008-04-29 2011-07-19 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
PE20110433A1 (es) * 2008-11-03 2011-07-09 Lilly Co Eli Antagonistas de la via hedgehog de ftalazina disustituida
PL2358698T3 (pl) 2008-11-17 2013-01-31 Lilly Co Eli Czteropodstawione pirydazyny jako antagoniści szlaku HEDGEHOG
JP5518088B2 (ja) * 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー 四置換ピリダジンヘッジホッグ経路アンタゴニスト
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
WO2012127441A1 (fr) 2011-03-23 2012-09-27 Semorex Technologies Ltd. Traitement des troubles de la prolifération
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
CN105017140B (zh) * 2014-04-28 2017-12-29 复旦大学 邻氨基苯甲酰胺化合物及其制备方法和用途
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
HRP20251395T1 (hr) 2015-06-04 2026-02-13 Sol-Gel Technologies Ltd. Topikalne formulacije za isporuku spojeva inhibitora hedgehog signalnog puta i njihova uporaba
CA2987067A1 (fr) * 2015-06-05 2016-12-08 Dana-Farber Cancer Institute, Inc. Composes et methodes de traitement du cancer
ES3057783T3 (en) 2016-03-15 2026-03-04 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases
CN106279114B (zh) * 2016-08-04 2019-01-29 东南大学 一种Taladegib的合成方法
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
CN106831718B (zh) * 2016-12-30 2019-05-07 上海科技大学 平滑受体配体及其应用
JP7323457B2 (ja) 2017-05-18 2023-08-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 肥満細胞疾患の処置のための方法及び医薬組成物
JP7327855B2 (ja) 2020-06-26 2023-08-16 ラクオリア創薬株式会社 レチノイドとがん治療薬との併用療法が有効ながん患者の選択方法およびレチノイドとがん治療薬との併用医薬
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
CN116349204A (zh) * 2020-10-13 2023-06-27 奋进生物医药公司 治疗纤维化的方法
US12447148B2 (en) 2024-03-05 2025-10-21 Endeavor Biomedicines, Inc. Methods of improving lung function
WO2025189041A1 (fr) * 2024-03-07 2025-09-12 Endeavor Biomedicines, Inc. Méthodes de traitement de la fibrose
WO2025242197A1 (fr) * 2024-05-24 2025-11-27 成都思倍博医药科技有限公司 Inhibiteur deutéré du récepteur smo de la voie hedgehog

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (fr) * 1977-06-03 1981-03-07 Pfizer
ZA97288B (en) 1996-01-15 1998-07-14 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
CA2326654C (fr) 1998-04-09 2010-11-09 Johns Hopkins University School Of Medicine Utilisation de derives steroides alcaloidiques servant d'inhibiteurs de voies de signalisation "hedgehog"
ES2233383T3 (es) 1999-06-08 2005-06-16 Lorantis Limited Utilizacion terapeutica de un ihibidor de la via de señalizacion hedgehog.
NZ530580A (en) * 2001-07-27 2007-02-23 Curis Inc Mediators of hedgehog signaling pathways, compositions and uses related thereto
AU2003231032B2 (en) 2002-04-22 2008-07-10 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
AU2003265853A1 (en) 2002-08-29 2004-03-19 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
WO2005080378A1 (fr) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation Dérivés de pyridazine fondue
WO2006004589A2 (fr) 2004-05-08 2006-01-12 Neurogen Corporation Pyridazines 3-aryl-5,6-disubstituees
KR20200019263A (ko) 2004-09-02 2020-02-21 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
EP1900731A1 (fr) * 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amides comme modulateurs du récepteur EP2
EP2137162B1 (fr) * 2007-03-15 2018-08-01 Novartis AG Composés organiques et leurs utilisations
ES2505091T3 (es) * 2007-06-25 2014-10-09 Amgen Inc. Compuestos, composiciones y métodos de uso de ftalazina
US8222251B2 (en) 2007-09-07 2012-07-17 Amgen Inc. Pyridopyridazine compounds, compositions and methods of use
CA2709203A1 (fr) * 2007-12-13 2009-06-18 Siena Biotech S.P.A. Antagonistes de la voie hedgehog et leurs applications therapeutiques
US7981892B2 (en) * 2008-04-29 2011-07-19 Eli Lilly And Company Disubstituted phthalazine hedgehog pathway antagonists
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
CA2732101C (fr) * 2008-08-04 2013-09-17 Amgen Inc. Modulateurs de kinase aurora et procedes d'utilisation
PE20110433A1 (es) 2008-11-03 2011-07-09 Lilly Co Eli Antagonistas de la via hedgehog de ftalazina disustituida
JP5518088B2 (ja) 2008-11-17 2014-06-11 イーライ リリー アンド カンパニー 四置換ピリダジンヘッジホッグ経路アンタゴニスト
PL2358698T3 (pl) 2008-11-17 2013-01-31 Lilly Co Eli Czteropodstawione pirydazyny jako antagoniści szlaku HEDGEHOG
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Also Published As

Publication number Publication date
CR20110658A (es) 2012-02-20
ZA201108587B (en) 2013-05-29
CO6480932A2 (es) 2012-07-16
DOP2011000386A (es) 2012-02-29
SI2443104T1 (sl) 2013-07-31
MX2011014029A (es) 2012-02-21
AU2010260244A1 (en) 2012-01-19
KR101389165B1 (ko) 2014-04-24
EA201270049A1 (ru) 2012-05-30
KR20120024783A (ko) 2012-03-14
PL2443104T3 (pl) 2013-08-30
US8273742B2 (en) 2012-09-25
EP2443104B1 (fr) 2013-04-17
ECSP11011541A (es) 2012-01-31
TN2011000627A1 (en) 2013-05-24
US20120316174A1 (en) 2012-12-13
CA2764542A1 (fr) 2010-12-23
AU2010260244B2 (en) 2013-09-05
HN2011003139A (es) 2013-07-29
BRPI1011601A2 (pt) 2016-03-22
CN102459233A (zh) 2012-05-16
TW201113268A (en) 2011-04-16
IL216599A (en) 2015-09-24
HRP20130408T1 (en) 2013-06-30
US20100324048A1 (en) 2010-12-23
PT2443104E (pt) 2013-05-07
NZ596882A (en) 2013-08-30
UA106755C2 (uk) 2014-10-10
CL2011003147A1 (es) 2012-07-20
JP2012530705A (ja) 2012-12-06
JO2931B1 (en) 2015-09-15
JP5596139B2 (ja) 2014-09-24
CN102459233B (zh) 2014-07-02
IL216599A0 (en) 2012-03-01
EP2443104A1 (fr) 2012-04-25
SG177289A1 (en) 2012-02-28
EA019059B1 (ru) 2013-12-30
AR077014A1 (es) 2011-07-27
PE20121050A1 (es) 2012-08-09
CA2764542C (fr) 2013-09-10
WO2010147917A1 (fr) 2010-12-23
MY156667A (en) 2016-03-15
HK1164872A1 (en) 2012-09-28
TWI385165B (zh) 2013-02-11
ES2409054T3 (es) 2013-06-24
US9000023B2 (en) 2015-04-07
DK2443104T3 (da) 2013-05-06

Similar Documents

Publication Publication Date Title
MA32726B1 (fr) Antagonistes phtalazine disubstituee de la voie de signalisation hedgehog
CR20110658A (es) Antagonistas de la trayectoria hedgehog de ftalazina desustituida
MA33244B1 (fr) Composes de vinylindazolyle
MA33224B1 (fr) Derives de proline comme inhibiteurs de la cathepsine
MA32349B1 (fr) Antagonistes de la voie hedgehog a base de phtalazines disubstituees
PA8713501A1 (es) INHIBIDORES DE 11-BETA HIDROXIESTEROIDE DEHIDROGENASA - 11ßHSD1
CL2012000311A1 (es) Compuestos derivados que contiene ciclos con 3 atomos de nitrogeno; utiles en el tratamiento de parasitosis en animales.
EP2464232A4 (fr) Composés d indazole inhibant la voie de signalisation des wnt et utilisations thérapeutiques de ceux-cithereof
MA34831B1 (fr) Amides d'aminoindanes presentant une forte activite fongicide et leurs compositions phytosanitaires
ECSP099550A (es) Nuevo procedimiento de síntesis de la agomelatina
CR10960A (es) Nuevo procedimiento de sintesis de la agomelatina
MA38218A1 (fr) Pyridine-2-amides utiles comme agonistes de cb2
BRPI0814772A2 (pt) Indazóis substituídos por 5-piridinona
FR2981934B1 (fr) Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
EA200870515A1 (ru) Моноциклические гетероарильные соединения
MA33824B1 (fr) Agonistes du recepteur mglu2
MA33430B1 (fr) Dérivés de pyrazinooxazépine
MA35097B1 (fr) Composition vaginale à base d'alkylpolyglucosides
TN2012000301A1 (fr) Utilisation du 2,3-dihydroxypropyl dodécanoate pour le traitement de la séborrhée
EA201100448A1 (ru) Соединения для связывания и визуализации амилоидных бляшек и их применение
CR10934A (es) Nuevo procedimiento de sintesis de la agomelatina
RU2008116559A (ru) Хлорсодержащие ароматические олигоэфиры
ATE474834T1 (de) Als agonisten des gpr38-rezeptors geeignete biarylverbindungen
ATE474574T1 (de) Imidazoazephinonverbindungen
UA108126C2 (uk) Спосіб отримання співполімеру натрійкарбоксиметилцелюлози й госиполу